NewAmsterdam Pharma Company N.V. NAMS 深 沪
等待开盘 04-02 09:30:00 美东时间
32.81
+0.800
+2.50%
华盛通- 最 高33.425
- 今 开32.61
- 成交量 99.54万股
- 最 低 31.53
- 昨 收 32.01
- 总市值 37.72亿
- 52周最高 42.00
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 14.92
- 委 比 -92.37%
- 总股本 1.15亿
- 历史最高 42.00
- 量 比 1.26
- 振 幅 5.92%
- 历史最低 5.6326
- 每 手 1
- 风险率 7.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NewAmsterdam Pharma will present data on its novel, oral, low-dose CETP inhibitor, obicetrapib, at ACC.26. The presentations will focus on its potential to preserve kidney function, safety, and cardiovascular outcomes in patients with elevated LDL-C. Obicetrapib has shown significant LDL-lowering effects with a favorable safety profile in Phase 3 trials. The company is advancing its clinical development, including the Phase 3 PREVAIL trial, with ...
03-23 12:00
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma announced the approval of inducement share options covering 10,000 ordinary shares and restricted stock units (RSUs) for 2,200 shares, granted to two non-executive new hires. The share options have an exercise price of $32.83, vesting over four years, with 25% after one year and the remainder in 36 monthly installments. The RSUs vest over three years, with one-third vesting annually. Both grants align with the 2024 Inducement ...
03-06 21:01
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
NewAmsterdam Pharma reports FY results
NewAmsterdam Pharma press release (NAMS): FY Revenue of $22.5M. Net loss for the year ended December 31, 2025, was $203.8 million, compared to net loss of $241.6 million in the year ended December 31,...
02-19 04:25
Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $48
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $46 to $48.
02-19 01:34
Earnings Summary: NewAmsterdam Pharma Co Q4
NewAmsterdam Pharma Co (NASDAQ:NAMS) announced its Q4 earnings on Wednesday, Fe...
02-18 22:22
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $47
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $44 to $47.
01-21 22:43
NewAmsterdam Pharma Issues Update On Obicetrapib Clinical Development Program And Outlines Strategic Priorities For 2026; EMA Approval Decision On Obicetrapib Anticipated In 2H26
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY ---- First patient
01-09 21:07
